On Jul. 12, 2016, Pfizer announced that Prevnar 13ﾮ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) received FDA approval for an expanded age indication to include adults 18 through 49 years of age, in addition to the already approved indication for adults 50 years and older, for active immunization for the prevention of pneumonia and invasive disease caused by 13 Streptococcus pneumoniae (S. pneumoniae) serotypes.